Bright Minds Biosciences

Historical price data

Bright Minds Biosciences is a mission-driven biotech focused on transforming treatment paradigms in CNS disorders through precision targeting of serotonin receptors. Founded in 2017, the company has rapidly advanced a proprietary platform to develop selective 5-HT2A and 5-HT2C agonists, deliberately engineered to avoid cardiotoxic 5-HT2B activity. Its strategy centers on de-risking clinical development through rigorous preclinical science and a deep, experienced leadership team. As a public company, it is positioned to leverage clinical milestones to address large, underserved markets in neurology and psychiatry.

A proprietary drug discovery platform combining computational chemistry, structural biology, and medicinal chemistry to design highly selective serotonin receptor agonists (targeting 5-HT2A, 5-HT2C) without 5-HT2B activity.

Competes against companies developing selective 5-HT2C/2A agonists and non-selective serotonergic agents. Key differentiation is the proprietary platform focused on avoiding cardiotoxic 5-HT2B activity, aiming for a superior safety profile versus older drugs and a more targeted approach than psychedelic-derived therapies.